logo
  

Vaxart Joins With Emergent To Advance Experimental COVID-19 Vaccine

Emergent BioSolutions Inc. (EBS) has entered into an agreement with Vaxart, Inc. (VXRT), under which Emergent has agreed to utilize its molecule-to-market contract development and manufacturing services to develop and manufacture Vaxart's experimental oral vaccine candidate for COVID-19. Emergent agreed to produce clinical material expected to enable Vaxart to initiate a Phase 1 clinical study anticipated early in the second half of 2020.

Emergent will provide development services out of its Gaithersburg, Md. location and manufacture drug substance at its Bayview facility in Baltimore, Md.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Lidl US has recalled its 8.4 oz Favorina branded Advent Calendar, i.e., Premium Chocolate with a Creamy Filling, citing potential Salmonella contamination, the U.S. Food and Drug Administration said. The products were available for sale at Lidl stores between October 12, 2022 and December 5, 2022. They will have a BEST IF USED BY year of 2023, and barcode number of 4056489516965. Vaccine partners Pfizer Inc. and BioNTech SE are seeking emergency use authorization or EUA from the U.S. Food and Drug Administration to offer their bivalent COVID-19 vaccine to children 6 months through 4 years of age. If authorized, the vaccine would be part of a primary series for children in this age group. Kraft Heinz Foods Co. is recalling around 2,400 pounds of ready-to-eat or RTE ham and cheese loaf products citing possible cross-contamination with under-processed products, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced.
Follow RTT